This Month in Psychopharmacology

Browsing articles in "Geriatric Psychiatry"

Physical Activity and Depression in Older Adults
July 24, 2023

A recent study investigated the most common causes of hospitalization due to physical conditions among people with depression. Data from a prospective, population-based cohort in the United Kingdom were used for primary analyses. Replication analyses included data from two ....

Continue reading (Members only)

Sleep-Disordered Breathing Tied to Brain Volumes in Amyloid-Positive Older Adults
June 19, 2023

Sleep-disordered breathing (SDB) has been associated with increased amyloid deposition and dementia risk; however, the details of that relationship are yet to be fully evident. A recent study investigated SDB and volume of medial temporal lobe subregions (associated with episodic memory and often affected in AD) and the impact of amyloid beta pathology in ..

Continue reading (Members only)

FDA Approves First Treatment for Agitation Associated with Alzheimer’s Dementia
May 10, 2023

The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application of brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia (AAD). This is the first FDA-approved treatment indicated for AAD in the United States...

Blood Test Predicts Which People With Amyloid Are Likely to Decline Cognitively
March 1, 2023

The pathology of Alzheimer’s disease (AD) begins with a prolonged phase of beta-amyloid accumulation without symptoms. The duration of this phase varies widely depending on the individual. A recent prospective population-based study examined data from 2 prospective longitudinal cohorts...

Continue reading (Members only)

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment
January 23, 2023

The U.S. Food and Drug Administration recently approved lecanemab, via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. This is the second of a novel category of medications approved for...

'Convincing Evidence' Hearing Aids Reduce Dementia Risk
December 20, 2022

With no truly effective treatment for dementia yet available, there is increased interest in lifestyle factors that may delay or prevent the onset of dementia. Previous studies have shown that hearing loss is associated with increased risk of dementia and cognitive decline. There are 3 main hypotheses for this association...

FDA Panel Rejects Pimavanserin for Alzheimer's Psychosis
June 21, 2022

A U.S. Food and Drug Administration advisory panel voted 9:3 against the supplementary new drug application pimavanserin for the treatment of hallucinations and delusions related to Alzheimer's disease psychosis...

Continue reading (Members only)

Opioids Linked to Increased Dementia Risk
June 6, 2022

NA recently published Israeli study examined the association between opioid use and the risk of incident dementia in old age based on a nationally-representative cohort. The researchers examined the relationship between opioid exposure and dementia in people who…...

Continue reading (Members only)

FDA Authorizes Marketing for New Test to Improve Diagnosis of Alzheimer’s Disease
May 9, 2022

The U.S. Food and Drug Administration (FDA) approved marketing authorizationnfor anst in vitro diagnostic test for the early detection of amyloid plaques, one of the pathological hallmarks associated with Alzheimer's adises. The test is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline...

Continue reading (Members only)

Impact of Neuropsychiatric Symptoms in Alzheimer’s Disease
March 4, 2022

Neuropsychiatric symptoms, including depression, apathy, and anxiety, are common among individuals with Alzheimer’s dementia. It is not yet clear the relationship among NPS, cognitive symptoms, and Alzheimer’s dementia neuropathology (which includes amyloid beta deposits, neurofibrillary tangles composed of hyperphosphorylated tau, and neurodegeneration). In this article...

Top of Page